CERK and breast carcinoma: NVP-231 treatment inhibited the growth of HCI-011-FR significantly more than HCI-011 (Figure 2D), further supporting our finding that ET-resistant breast cancer models are more sensitive to CERK inhibition than ET-sensitive models.